Last updated September 9, 2026
Key finding
The BBT+E group exhibited a significantly higher TIR from day 2, exceeding 70% by day 5.
This study evaluated the impact of adding SGLT2 inhibitors to basal bolus therapy in hospitalized patients with type 2 diabetes, finding improved glycemic control.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the impact of adding SGLT2 inhibitors to basal bolus therapy in hospitalized patients with type 2 diabetes, finding improved glycemic control.
Improving glycemic control in hospitalized patients is crucial as it can lead to better recovery outcomes and reduce complications. This study suggests that incorporating SGLT2 inhibitors like empagliflozin into standard insulin regimens may enhance patient care and management of diabetes during hospitalization.
The study's sample size and specific hospital setting may limit generalizability. Potential confounding factors were not fully controlled. Long-term effects of the therapy combination were not assessed.
Published in
Publication details and source links for this paper.
Nobutoshi F, Hiroki H, Tatsuya I, et al. The addition of SGLT2 inhibitors to basal bolus therapy improves glycemic control in hospitalized patients with type 2 diabetes. Endocrinology, Diabetes & Metabolism. 2025;8(5):e70096. doi:10.1002/edm2.70096
The BBT+E group exhibited a significantly higher time in range, exceeding 70% by day 5.
Blood glucose levels declined more rapidly in the BBT+E group, with a significant decrease of 20 mg/dL (p=0.021).
The BBT+E group had reduced insulin requirements, needing 5 fewer units on average.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Basal bolus therapy, Basal bolus therapy with empagliflozin and Change in ketone body levels after combination therapy, Daily glucose average, Time above range, and 3 more.
This study contributes evidence to
Primary intervention
Basal bolus therapy
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
2
Related topics
12
Evidence pairs
581
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
matched_outcome
Related evidence
Evidence topic
Save evidence
Core evidence
The primary outcomes reported in this study.
Basal bolus therapy → Change in ketone body levels after combination therapy
Basal bolus therapy → Change in ketone body levels after combination therapy
Basal bolus therapy → Daily glucose average
Basal bolus therapy → Daily glucose average
Basal bolus therapy → Total daily insulin dose
Basal bolus therapy → Total daily insulin dose
Basal bolus therapy with empagliflozin → Change in ketone body levels after combination therapy
Basal bolus therapy with empagliflozin → Change in ketone body levels after combination therapy
Basal bolus therapy with empagliflozin → Daily glucose average
Basal bolus therapy with empagliflozin → Daily glucose average
Basal bolus therapy with empagliflozin → Time above range
Basal bolus therapy with empagliflozin → Time above range
Basal bolus therapy with empagliflozin → Time below range
Basal bolus therapy with empagliflozin → Time below range
Basal bolus therapy with empagliflozin → Time in range
Basal bolus therapy with empagliflozin → Time in range
Basal bolus therapy with empagliflozin → Total daily insulin dose
Basal bolus therapy with empagliflozin → Total daily insulin dose
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Basal bolus therapy and Daily glucose average, Basal bolus therapy and Insulin Resistance.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies on Basal bolus therapy
Contributes to Basal bolus therapy evidence base.
All studies measuring Daily glucose average
Measures Daily glucose average as a key outcome.
All studies measuring Insulin Resistance
Measures Insulin Resistance as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Basal bolus therapy with empagliflozin appears to improve daily glucose average.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Daily glucose average
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Basal bolus therapy with empagliflozin appears to improve time above range.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Time above range
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Basal bolus therapy with empagliflozin appears to improve time in range.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Time in range
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Basal bolus therapy for change in ketone body levels after combination therapy.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Change in ketone body levels after combination therapy
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
